Evidence map›Paper›PMID 39773358›Full record

ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025

Ultrasound super-resolution imaging for non-invasive assessment of microvessel in prostate lesion.

Xin Huang, Huarong Ye, Yugang Hu, Yumeng Lei, Yi Tian, Xingyue Huang, Jun Zhang, Yao Zhang, Bin Gui, Qianhui Liu and 2 more

Abstract read
In one paragraph

Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xin Huang *Department of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Huarong Ye *Department of Medical Ultrasound, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, China.
Yugang HuDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Yumeng LeiDepartment of Medical Ultrasound, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, China.
Yi TianDepartment of Medical Ultrasound, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, China.
Xingyue HuangDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Jun ZhangDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Yao ZhangDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Bin GuiDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Qianhui LiuDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Ge ZhangDepartment of Medical Ultrasound, China Resources & Wisco General Hospital, Wuhan University of Science and Technology, Wuhan, 430080, China. zhang.ge1@qq.com.
Qing DengDepartment of Ultrasound Imaging, Renmin Hospital of Wuhan University, Wuhan, 430060, China. wudadq@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the leading cause of cancer-related morbidity and mortality in men worldwide. An early and accurate diagnosis is crucial for effective treatment and prognosis. Traditional invasive procedures such as image-guided prostate biopsy often cause discomfort and complications, deterring some patients from undergoing these necessary tests. This study aimed to explore the feasibility and clinical value of using ultrasound super-resolution imaging (US SRI) for non-invasively assessing the microvessel characteristics of prostate lesion.

methodsThis study included 127 patients with prostate lesion who presented at Renmin Hospital of Wuhan University between November 2023 and June 2024 were included in this study. All the patients underwent transrectal US (TRUS), contrast-enhanced US (CEUS), and US SRI. CEUS parameters of time-intensity curve (TIC): arrival time (AT), rising time (RT), time to peak (TTP), peak intensity (PKI), falling time (FT), mean transit time (MTT), ascending slope (AS), descending slope (DS), D/A slope ratio (SR), and area under the TIC (AUC). US SRI parameters: microvessel density (MVD), microvessel diameter (D), microvessel velocity (V), microvessel tortuosity (T), and fractal number (FN), were analyzed and compared between prostate benign and malignant lesion.

resultsThe tumor markers of prostate in the malignant group were all higher than those in the benign group, and the differences were statistically significant (P < 0.001). The TIC parameters of CEUS revealed that the PKI, AS, DS, and AUC were significantly higher in the malignant group than in the benign group (P < 0.001), whereas the RT, TTP and FT in the malignant group were significantly lower (P < 0.001). Malignant lesion exhibited significantly higher MVD, larger D, faster V, greater T, and more complex FN than benign lesion (P < 0.001).

conclusionsUS SRI is a promising non-invasive imaging modality that can provide detailed microvessel characteristics of prostate lesion, offering an advancement in the differential diagnosis for prostate lesion. And, US SRI may be a valuable tool in clinical practice with its ability to display and quantify microvessel with high precision.

Indexed as

MicrovesselsProstatic NeoplasmsUltrasonographyAgedContrast MediaFeasibility StudiesHumansMaleMiddle AgedProstateContrast MediaMicrovesselNon-invasive diagnosisProstate lesionUltasound super-resolution imaging

Identifiers

PMID39773358
PMCPMC11706184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.